Literature DB >> 8614504

Clinical and neuropsychological characteristics in familial and sporadic Alzheimer's disease: relation to apolipoprotein E polymorphism.

M Lehtovirta1, H Soininen, S Helisalmi, A Mannermaa, E L Helkala, P Hartikainen, T Hänninen, M Ryynänen, P J Riekkinen.   

Abstract

Alzheimer's disease (AD) is a heterogeneous entity presenting as sporadic and familial disease. In familial AD, there is evidence for genetic linkage to a yet undefined gene on chromosome 14 in early-onset pedigrees and on chromosome 19 in late-onset pedigrees. In a few early-onset kindreds, there were mutations in the amyloid precursor gene on chromosome 21. There is an increased frequency of apolipoprotein E (ApoE) epsilon4 allele in patients with late-onset AD. We studied the clinical presentation and profile of cognitive deficits in 58 AD patients at the early stage of the disease. We divided the AD patients into subgroups of sporadic late-onset (SLO) (> or = 65 years), familial late-onset (FLO) (> or = 65 years), sporadic early-onset (SEO) (<65 years), and familial early-onset (FEO) (<65 years) patients and into three subgroups according to their ApoE genotype zero epsilon4, one epsilon4, and two epsilon4 alleles. The AD subgroups did not differ in the global clinical severity of dementia or the duration of the disease. SLO, FLO, SEO, and FEO subgroups did not differ in clinical characteristics such as occurrence of rigidity, hypokinesia, tremor, myoclonus, hallucinations, delusions, or epileptic seizures nor in the profile of deficits on tests assessing memory, language, visuospatial, executive, and praxic functions. The epsilon4++ allele frequency was 0.43 for all AD patients and did not differ across subgroups divided according to the familial aggregation and age of onset. Patients with two epsilon4 alleles had earlier age at onset of dementia than those with no epsilon4 allele (63 +/- 9 versus 68 +/- 9 years), but otherwise the clinical symptoms and signs were not related to the ApoE genotype. However, the AD patients with two epsilon 4 alleles had lowest scores on memory tests and differed significantly from those with one or zero epsilon4 allele in the delayed list learning (p<0.05) and from those with zero epsilon4 allele in the immediate and delayed story recall. In contrast, verbal functions were better preserved in two epsilon4 patients than in those with other ApoE genotypes. This study failed to confirm the earlier reports of severe aphasia, agnosia, and apraxia in familial AD patients, but the clinical phenotype was similar irrespective to the familial aggregation. However, AD patients with two epsilon4 alleles are characterized by more severe memory loss and earlier age of onset than those without the epsilon4 allele.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8614504     DOI: 10.1212/wnl.46.2.413

Source DB:  PubMed          Journal:  Neurology        ISSN: 0028-3878            Impact factor:   9.910


  36 in total

1.  Apolipoprotein E epsilon4 allele decreases functional connectivity in Alzheimer's disease as measured by EEG coherence.

Authors:  V Jelic; P Julin; M Shigeta; A Nordberg; L Lannfelt; B Winblad; L O Wahlund
Journal:  J Neurol Neurosurg Psychiatry       Date:  1997-07       Impact factor: 10.154

Review 2.  Brain fuel metabolism, aging, and Alzheimer's disease.

Authors:  Stephen Cunnane; Scott Nugent; Maggie Roy; Alexandre Courchesne-Loyer; Etienne Croteau; Sébastien Tremblay; Alex Castellano; Fabien Pifferi; Christian Bocti; Nancy Paquet; Hadi Begdouri; M'hamed Bentourkia; Eric Turcotte; Michèle Allard; Pascale Barberger-Gateau; Tamas Fulop; Stanley I Rapoport
Journal:  Nutrition       Date:  2010-10-29       Impact factor: 4.008

3.  Genetic analysis of BDNF and TrkB gene polymorphisms in Alzheimer's disease.

Authors:  Saila Vepsäläinen; Eero Castren; Seppo Helisalmi; Susan Iivonen; Arto Mannermaa; Maarit Lehtovirta; Tuomo Hänninen; Hilkka Soininen; Mikko Hiltunen
Journal:  J Neurol       Date:  2005-02-23       Impact factor: 4.849

4.  Association of CYP46 intron 2 polymorphism in Finnish Alzheimer's disease samples and a global scale summary.

Authors:  S Helisalmi; S Vepsäläinen; A M Koivisto; A Mannermaa; S Iivonen; M Hiltunen; V Kiviniemi; H Soininen
Journal:  J Neurol Neurosurg Psychiatry       Date:  2006-03       Impact factor: 10.154

5.  Insulin-degrading enzyme is genetically associated with Alzheimer's disease in the Finnish population.

Authors:  Saila Vepsäläinen; Michele Parkinson; Seppo Helisalmi; Arto Mannermaa; Hilkka Soininen; Rudolph E Tanzi; Lars Bertram; Mikko Hiltunen
Journal:  J Med Genet       Date:  2007-05-11       Impact factor: 6.318

6.  Apolipoprotein E (APOE) genotype has dissociable effects on memory and attentional-executive network function in Alzheimer's disease.

Authors:  David A Wolk; Bradford C Dickerson
Journal:  Proc Natl Acad Sci U S A       Date:  2010-05-17       Impact factor: 11.205

7.  Major decrease in the volume of the entorhinal cortex in patients with Alzheimer's disease carrying the apolipoprotein E epsilon4 allele.

Authors:  K Juottonen; M Lehtovirta; S Helisalmi; P J Riekkinen; H Soininen
Journal:  J Neurol Neurosurg Psychiatry       Date:  1998-09       Impact factor: 10.154

8.  Somatostatin genetic variants modify the risk for Alzheimer's disease among Finnish patients.

Authors:  Saila Vepsäläinen; Seppo Helisalmi; Anne M Koivisto; Toni Tapaninen; Mikko Hiltunen; Hilkka Soininen
Journal:  J Neurol       Date:  2007-11-09       Impact factor: 4.849

Review 9.  Genomic variants, genes, and pathways of Alzheimer's disease: An overview.

Authors:  Adam C Naj; Gerard D Schellenberg
Journal:  Am J Med Genet B Neuropsychiatr Genet       Date:  2017-01       Impact factor: 3.568

10.  SPECT and MRI analysis in Alzheimer's disease: relation to apolipoprotein E epsilon 4 allele.

Authors:  M Lehtovirta; H Soininen; M P Laakso; K Partanen; S Helisalmi; A Mannermaa; M Ryynänen; J Kuikka; P Hartikainen; P J Riekkinen
Journal:  J Neurol Neurosurg Psychiatry       Date:  1996-06       Impact factor: 10.154

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.